Sign up to our newsletter Subscribe
Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Sign up to our newsletter Subscribe
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
An error has occurred, please try again later.